Orion Biotechnology Canada, Ltd. products
Precision-Engineered GPCR-Targeted Therapeutics
Orion’s platform and science unlocks the therapeutic potential of GPCR targets across a broad range of medical needs. Our approach allows us to focus our discovery and development efforts across peptide and protein GPCR subfamilies, generating a diversified pipeline of potential first-in-class/best-in-class antagonist and agonist therapies against high-value GPCR targets in oncology, immunology and other serious diseases.
G Protein-Coupled Receptors (GPCRs)
G Protein-Coupled Receptors (GPCRs) are involved in a wide range of physiological and pathological processes and represent a large class of drug targets accounting for >30% of all drugs on the market. These drugs, however, only cover 15% of the entire GPCR family, and many valuable receptors remain undrugged. In particular, GPCRs whose natural ligands are large peptides or small proteins are challenging for drug development due to their large and complex binding pockets.